• Biospecimen SolutionsPrecision Value & HealthCareers
    P_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGB
    • Clinical
      Trial Services
        • Overview
            • Oncology Clinical TrialsImage

              Oncology Clinical Trials


              Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

              • Rare & Orphan DiseaseImage

                Rare & Orphan Disease


                With experience built on 150+ orphan disease projects covering 80+ rare diseases, we know how to anticipate logistical and regulatory obstacles and craft bold solutions that drive rare disease development programs.

        • Global Clinical Trial Support –
            • North & South America –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Europe –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • APAC –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

        • Clinical Trial Management –
            • Study Start-up & Feasibility –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Project Management –
            • Patient Recruitment –
            • Personalized Clinical Trial Operations –
            • Biometrics –
            • Medical & Safety Monitoring –
            • Clinical Data Management –
            • Medical Writing –
        • Clinical Development Strategy –
            • Clinical Development Planning –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Biomarker Strategies –
            • Cell & Gene Therapy Strategies –
            • CDx Regulatory and Market Access –
        • Clinical Trial Design –
            • Basket & Umbrella Trials –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Biomarker Clinical Trials –
            • Master Protocol Trials –
            • Decentralized Clinical Trials
        • Biostatistics –
            • Statistical Consulting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Study Design –
            • Data Monitoring Committees –
            • CDISC Programming and Documentation –
            • eCTD Submissions –
        • Central Lab Services –
            • Clinical Specimen Kitting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Sample Processing –
            • Global Specimen Logistics and Biostorage –
            • Biospecimen Data Services –
            • Precision Lab e-Portal –
            • Virtual Sample Inventory Management –
        • Training
            • Oncology Clinical TrialsImage

              Oncology Clinical Trials


              Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

              • Rare & Orphan DiseaseImage

                Rare & Orphan Disease


                With experience built on 150+ orphan disease projects covering 80+ rare diseases, we know how to anticipate logistical and regulatory obstacles and craft bold solutions that drive rare disease development programs.

    • Lab
      Services
        • Central Lab Services –
            • Clinical Specimen Kitting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Sample Processing –
            • Global Specimen Logistics and Biostorage –
            • Biospecimen Data Services –
            • Precision Lab e-Portal –
            • Virtual Sample Inventory Management –
        • Specialty Lab Services Overview –
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

        • EU Contract Research Organization –
        • Immune Monitoring –
            • Immune Monitoring by Flow Cytometry –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • Immune Cell Phenotyping by Epiontis ID –
            • Cytokine Profiling –
            • Gene Expression Profiling –
            • ELISpot and FluoroSpot –
            • Custom Assays –
        • Flow Cytometry –
            • Receptor Occupancy Assays by Flow Cytometry –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

        • Genomics –
            • NanoString Assays –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • ddPCR –
            • qPCR –
            • NGS –
            • Fluorescence In Situ Hybridisation (FISH) / ISH –
        • Tissue & Liquid Biopsy –
            • ApoStream – CTC and Rare Cell Isolation for Liquid Biopsy
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • CTC / cfDNA / Exosome Analysis –
            • Multiplex Immunofluorescence –
            • Immunohistochemistry –
            • Fluorescence In Situ Hybridisation (FISH) / ISH
            • Pathology Services –
            • NanoString Assays
        • Bioanalytical Testing –
            • Immunogenicity Testing –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • PK Assays –
            • ADA Assays –
            • MesoScale Discovery (MSD) Assays –
            • Quanterix SIMOA –
            • ELISA
        • Cytokine Analysis –
            • ELISA –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • MesoScale Discovery (MSD) Assays
            • Luminex –
            • Quanterix SIMOA
        • Preclinical Target and Biomarker Validation –
            • Cell Based Assays –
            • Target Expression – XpressWay Profiles –
            • Tissue Cross-Reactivity –
            • Fluorescence In Situ Hybridisation (FISH) / ISH –
            • Multiplex Immunofluorescence –
            • Immunohistochemistry (IHC)
        • Biospecimens
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

    • Data
      Sciences
        • Overview
            • BiostatisticsImage

              Biostatistics


              Seasoned biostatisticians and statistical programmers support every phase of your trial, from study design for small, rare disease trials to regulatory submissions, all backed by meticulous documentation.

              • QuartzBioImage

                QuartzBio


                Purpose-built technology engineered specifically to reach across data silos and address the challenges of both sample data and biomarker data management— providing a single, scalable data platform solution.

        • Biostatistics
        • Clinical Data Management
        • Biometrics
        • QuartzBio –
            • Biomarker Data Management –
              • BiostatisticsImage

                Biostatistics


                Seasoned biostatisticians and statistical programmers support every phase of your trial, from study design for small, rare disease trials to regulatory submissions, all backed by meticulous documentation.

            • Virtual Sample Inventory Management –
    • Diagnostics
      & CDx
        • IVD and CDx Regulatory Affairs Consulting –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • COVID-19 & Viral Panel Assays –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Biospecimens Solutions 
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Diagnostic Market Access Services –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Companion Diagnostics
    • Therapeutic
      Areas
        • Overview
            • By Specialty Area
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • Oncology and Immuno-Oncology
              • Oncology Clinical Trials
            • Rare & Orphan Disease
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • Cell & Gene Therapy
              • Cell Therapy
              • Gene Therapy
              • Cell and Gene Therapy Manufacturing
            • CNS & Neuroscience
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • COVID-19
            • AutoImmune & Allergy
            • Pediatric
        • By Research Phase
        • Preclinical Development –
        • Early Phase Trials (I-IIa) –
        • Late Phase Trials (IIb-III) –
    • News &
      Insights
        • Blog –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

        • Resources –
        • Thought Leadership –
        • News –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

        • Events –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

    • About
      Us
        • Our Passion –
            • Patient RecruitmentImage

              Our Passion


              What we do, why we do it and the principles that guide us every day.

              • meet-our-peopleImage

                Meet Our People


                We are devoted professionals with deep expertise in translational science, clinical trials and data sciences.

        • Meet Our People –
        • Careers
        • Regulatory Information –
            • Patient RecruitmentImage

              Our Passion


              What we do, why we do it and the principles that guide us every day.

              • meet-our-peopleImage

                Meet Our People


                We are devoted professionals with deep expertise in translational science, clinical trials and data sciences.

    • Contact
      Us
    • Home
    • Technologies that Make Decentralized Clinical Trials Tick
    Blog Clinical Research Insights Translational & Lab Insights
    Article

    Technologies that Make Decentralized Clinical Trials Tick

    Written By Maggie Bloomberg
    March 15, 2022 • 8 min. read

    Can technological solutions support successful DCTs?

    At the start of the COVID-19 pandemic, the world turned to technology for novel solutions to an at-the-time novel virus. In the clinical trial space, these increasingly open mindsets accelerated the acceptance and adoption of decentralized clinical trial (DCT) strategies and technologies — a silver lining that came at high cost.

    The potential benefits offered by DCTs have broad application. For the 4% of the global population diagnosed with one of 7,000 different rare diseases, however, the impact is amplified. Rare and orphan diseases can include genetic, environmental, and infectious illnesses, in addition to rare cancers. The technological advantages to DCTs can reduce barriers to participation, ease hurdles to access, and strengthen retention throughout a study’s duration.

    Importantly and fundamentally, DCTs harness technological advancements that help bridge the myriad gaps between patients and researchers, and the treatments aimed at meeting unmet medical needs. This article will explore how technology and DCTs close those gaps in terms of geography, study design, and the particular physical, financial, emotional, and other challenges that make rare disease trials uniquely complex.

    Technology in DCTs reduces burdens and barriers for patients and providers

    Rare diseases can often present a spectrum of neurological, behavioral, and physiological symptoms, all of which can range from mild to severe. This variation may even exist within patient groups of the same rare disease diagnosis. Designing a successful rare disease trial entails planning how patients will be able to participate in the trial, including traveling to the clinical site and suitable accommodations. Some symptoms of rare diseases make it complicated and burdensome for patients to travel, necessitating specialized arrangements and equipment, such as long-distance impulse sensitive ambulances with oxygen tanks.

    Pediatric patients or those with developed symptoms usually require a caregiver during the trips to trial sites. The caregiver—who may be a family member, hired nurse, or another individual—should make the necessary arrangements to attend appointments, which may include requesting time off from work or arranging care for other possible dependents. The duties and obligations of a caregiver can present considerable logistical, financial, and emotional burdens. Fortunately, stress and responsibilities related to caregiving can also be reduced with the technological solutions inherent to DCTs.

    Instead of requiring patients to undertake the arduous journey to clinical sites, DCTs can implement telemedicine visits for screenings and study visits, thereby reducing a substantial portion of burdensome travel. Two-way, opt-in policies and Informed Consent Form (eConsent) technology enables patients and/or family members to give informed consent via a simple downloadable app. DCTs grant patients and caregivers more freedom throughout the trial. When they can start the screening process in advance from the comfort and convenience of their own homes, patients feel more respected, involved, empowered, and in control.

    Virtual sites, telemedicine, and home health systems and solutions

    Virtual clinical sites are valuable because they reduce or eliminate the need to open a stand-alone clinical trial site near individual rare disease trial participants, which is often necessary when patients are in rural areas. While not ideal for all cases, virtual sites support patient-facing activities with technology like Remote Patient Monitoring (RPM) solutions and Direct-to-Patient Investigational Product (IP) shipments. Resources that would have otherwise been spent on establishing and operating physical trial sites can be reallocated to improve the overall trial and patient outcomes, especially by incorporating more ways to enhance the experience of patients and family members.

    Sponsors can also utilize a variety of telemedicine and home health solutions when designing and conducting rare disease DCTs, ensuring a patient-centric approach that supports family members and caregivers. Telemedicine, whether via computers or mobile devices, enables continuous, close communication and instant data sharing, which are essential to maintain study integrity and achieve successful research results. Sponsors can coordinate cohesive and comprehensive care among the entire medical team (including the investigator and standard of care provider). Additionally, practitioners can schedule and hold appointments with patients, family members, and caregivers, and even obtain samples and biopsies without traveling long distances.

    Home health not only reduces travel and financial burdens, but it enables patients to engage with the same healthcare workers throughout the study. This provides patients and family members with an important foundation on which to build a trusting and reliable relationship. A trusted nurse can provide emotional support, counseling, and coaching, in addition to helping navigate trial protocols and gathering health data—all crucial factors in creating a positive trial experience and deeper connection to the study for patients and family members.

    Furthermore, patients and caregivers are more likely to be candid about symptoms or side effects with practitioners they trust, resulting in more accurate study data. In turn, healthcare professionals can react quickly and find solutions in case any issues arise, particularly while using real-time RPM technology.

    Remote patient monitoring benefits people, families, and practitioners

    RPM solutions, such as Electric Patient Reported Outcome (ePRO), eDiaries, and wearable technology help gather important health data at more optimal intervals, more efficiently, and with greater accuracy compared to traditional methods. Chosen technology assists rare disease DCT sponsors in maintaining the exacting data recording and monitoring process. The data gathered and stored can shine new light on factors and situations in a rare disease patient’s life which illustrate more authentic real-world scenarios and associated evidence.

    ePROs and eDiaries offer an effective alternative to the traditional paper questionnaires and booklets previously employed to gather data from patients and caregivers during trials. If paper questionnaires are damaged or misplaced over the course of a study, significant data could be excluded from the analysis, possibly skewing the results, implications, and future developments. As an alternative, patients with rare diseases who are part of DCTs and their caregivers can use their personal devices (via downloadable software) and/or sponsor-provided devices to record important data (e.g., received treatments, vital signs, physical examinations, sleep patterns, and emotional and mental well-being). Some software or hardware can also remind patients and caregivers to administer scheduled treatments as well as input the proper data in a timely fashion.

    To further support patients with rare diseases and their care team during DCTs, sponsors are strongly encouraged to consider incorporating sensors and wearable technology in clinical studies. Solutions that automatically measure and record the relevant data reduce the burden on patients and caregivers since they are not required to manually assess and record health data. The health data can be directly transferred to a clinical site or team in near real-time and will be more accurate due to minimized human error.

    Since the data can be received and read almost immediately, the medical team can react quickly to concerning incidents and determine appropriate solutions. Additionally, anomalies (such as a recorded high heart rate due to exercise or an exciting event) can also be noted and disregarded in the data pool, ensuring a robust fact-based data analysis with minimized outliers.

    With RPM, telemedicine, and more, study plan designs must factor in the different types of biometrics, imaging, software, hardware, and other technology that will be integrated into the trial. Sponsors must remain mindful during the study planning process that all these components operate in sync; for example, home health and RPM, as intended within the trial protocol and ICF. Because DCT technology and traditional clinical research methods are increasingly being used together in hybrid trial models, it is advantageous for sponsors who are interested in implementing DCT strategies to consult with experienced CROs and vendor partners.

    Building in flexibility establishes trust

    A final factor is not a technology itself, but it can be fortified by technology and the ways in which technology is activated in DCTs. That factor is trust: It is essential to any trial and without it, clinical development would certainly come to a standstill.

    Rare diseases are present globally, therefore the cultures and healthcare systems that patients and practitioners experience—and that sponsors must plan for—can vary greatly. Healthcare systems may be more centralized or decentralized, with actors such as social security and insurance organizations also taking on different roles according to the region. Some healthcare systems are extremely complicated, and DCT designs can simplify orchestrating and conducting clinical research, increasing accessibility, and making it easier to carry out rare disease trials on a global scale. Such simplifications can inspire patient trust.

    Regardless of the culture and the healthcare system, there must be a foundation of trust among patients, their family members, and healthcare practitioners (such as home health nurses or sponsors). Building this foundation hinges on understanding and accounting for the needs, expectations, and resources of everyone involved.

    For rare disease patients and their family members, feeling that they’re heard and adequately involved in the trial is a fundamental component to establishing trust. In addition to being acknowledged, patients and their loved ones may consider it important that certain courses of action are taken as well. The more flexible a study is, the easier it is for healthcare providers to accommodate the patients’ and family members’ wishes. Rare disease studies designed based on DCT principles supply the flexibility needed to solve challenges, reduce burdens, and cultivate important long-term relationships based on trust.

    Conclusion

    Decentralized trial designs are well suited to rare disease clinical development and can reduce the numerous burdens rare disease patients, family members, and caregivers face. DCT strategies provide substantial benefits in the form of flexible hybrid model study protocols, which are crucial to achieving patient enrollment diversity goals. Solutions such as telemedicine, home health, RPM, and wearable technology enable clinical researchers to include people with rare disease regardless of their location.

    The pandemic brought many of these technologies to the forefront of clinical development and bolstered the creation of innovative, market-shifting solutions. DCT strategies and technology are now firmly established in the clinical development sphere and will continue to enable and advance rare disease research.

    Every study is unique. If you have questions about decentralized trial strategies, you can contact us, or you can learn more about Precision’s approach to decentralize clinical trials.


    • Maggie Bloomberg

      Maggie Bloomberg is an Associate Director of Project Management at Precision for Medicine. She brings more than 17 years of Clinical experience to the Precision team. Maggie’s expertise covers a wide variety of therapeutic areas, including but not limited to, rheumatology, oncology, neurology, endocrinology and cardiology.

    Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

    Visit the website
    Clinical Trial Services
    • Overview
    • Global Clinical Trial Support
    • Clinical Trial Management
    • Clinical Development Strategy
    • Clinical Trial Design
    • Biostatistics
    • Clinical Sample Management
    • Clinical Research Organization
    Specialty Lab Services
    • Overview
    • Immune Monitoring
    • Flow Cytometry
    • Genomics
    • Tissue & Liquid Biopsy
    • Bioanalytical Testing
    • Cytokine Analysis
    • Biospecimens
    • Sample Processing
    • Global Specimen Transport & Biostorage
    • Contract Research Organization
    • Bioanalysis
    • Neutralizing Antibody (NAb) Assays
    • PBMC Processing
    Data Sciences
    • Overview
    • Biostatistics
    • Clinical Data Management
    • Biometrics
    • QuartzBio
    • Virtual Sample Inventory Management
    Therapeutic Expertise
    • Overview
    • Preclinical Development
    • Early Phase Trials (I-IIa)
    • Late Phase Trials (IIb-III)
    • Oncology and Immuno-Oncology
    • Rare & Orphan Disease
    • Cell & Gene Therapy
    • Neurology
    • COVID-19
    • Autoimmune & Allergy
    • Pediatric
    • Companion Diagnostics
    About Us
    • Our Passion
    • Meet Our People
    • Careers
    • ESG Policy
    • Regulatory Information

    News & Insights
    • Publications
    • Case Studies
    • Thought Leadership
    • News
    • Events
    © 2023 Precision Medicine Group, LLC. All rights reserved. Privacy Policy    GDPR